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SUMMARY
Nowadays leishmaniasis is an increasing, severe, public
health problem, and its control is strictly connected to vaccine
development and therapeutic manipulations of the immune sys-
tem. The clinical outcome of leishmaniasis is related to
cytokine response profile. Immune system type-1 response and
IFN-g production provide well-known protective activity
against Leishmania, whereas role of T helper (TH) 2 cytokines
in non-healing infections requires further exploration. As a
matter of fact, IL-4 and IL-13 (TH2 cytokines) promote disease
progression in cutaneous leishmaniasis, whereas IL-4 seems to
enhance protective type-1 responses in visceral leishmaniasis.
Thus, immune response to intracellular parasites should dis-
miss the TH1/TH2 paradigm of resistance/susceptibility,
embracing theory of a more complicated network of regulato-
ry/counter regulatory interactions. Moreover, the presence of
antigen specific regulatory T cell subsets may provide an envi-
ronment that contributes to the balance between TH1 and TH2
cells. Finally, the involvement of CD8+ T cells has been
described, but the modality of their role and function, in this
kind of infection, has not been outspreed so far.
Key words: Cutaneous leishmaniasis, Visceral leishmaniasis,
TH1/TH2 paradigm, citokines, chemokines, apoptosis
RIASSUNTO
Le leishmaniosi rappresentano, attualmente, un grave
problema di salute pubblica, epidemiologicamente in aumento,
ed il loro controllo è strettamente connesso allo sviluppo di
vaccini e di particolari manipolazioni farmacologiche del
sistema immunitario. Il risultato clinico delle leishmaniosi,
guarigione o meno, è legato al profilo citochinico della rispo-
sta immune. Le risposte immunologiche di tipo 1 e la produzio-
ne di IFN-γ forniscono un potente effetto di protezione contro
le leishmanie, mentre il supposto ruolo peggiorativo dei linfo-
citi T helper (TH) 2 e delle citochine da essi prodotte, nelle
infezioni da leishmanie non guarite, richiede ulteriori
approfondimenti. È un dato di fatto che l’IL-4 e l’IL-13 (cito-
chine TH2) siano in grado di promuovere la progressione della
malattia nella leishmaniosi cutanea, mentre l’IL-4 sembra
aumentare l’effetto protettivo delle risposte TH1 nella leishma-
niosi viscerale. Quindi, la risposta immunologica nei confronti
di questi parassiti intracellulari non sembra adattarsi perfetta-
mente al noto paradigma TH1/TH2 di resistenza/suscettibilità,
teoria semplificata di una certamente più complessa rete di
interazioni fra meccanismi regolatori e contro regolatori
immunologici. Inoltre, la presenza di cellule T antigene-specifi-
che a funzione regolatrice potrebbe creare un peculiare milieu,
che può, a sua volta, contribuire all’equilibrio funzionale tra
cellule TH1 e TH2. Infine, nelle leishmaniosi, è stato descritto,
anche, il coinvolgimento delle cellule T CD8+, ma loro ruoli e
funzioni, in questo particolare tipo di infezione, non sono stati
ancora ben definiti.
Parole chiave: Leishmaniosi cutanea, leishmaniosi viscerale-
paradigma TH1/TH2, citochine, chemochine, apoptosi
Acta Medica Mediterranea, 2011, 27: 7
ADVANCES IN LEISHMANIASIS IMMUNOPATHOGENESIS
PASQUALE MANSUETO*, GIUSTINA VITALE*, AURELIO SEIDITA*, FRANCESCO PAOLO GUARNERI*, ILENIA PEPE*, CARMELINA
RINOLLO*, SALVATORE DI ROSA**, GIOVAMBATTISTA RINI*, ENRICO CILLARI***, GAETANA DI FEDE^
*Internal Medicine, Department of Clinical Medicine and Emerging Diseases, University Hospital of Palermo, Italy - **Azienda
Ospedaliera Ospedali Riuniti ‘Villa Sofia-Cervello’, Palermo - ***U.O. di Patologia Clinica, P.O. ‘Cervello’, Azienda Ospedaliera
Ospedali Riuniti ‘Villa Sofia-Cervello’, Palermo - ^Surgery Department, University Hospital of Palermo, Palermo, Italy
[Recenti progressi nell’immunopatogenesi delle leishmaniosi]
Introduction
Supervisory of public health should consider
leishmaniasis a severe, increasing, health problem(1-2).
Infective diseases affect more than 50 million
people who travel from industrialized to developing
countries each year; leishmaniasis, which is endem-
ic in the areas of tropics, subtropics, and southern
Europe, is one(3).
Therapeutic manipulations of the immune sys-
tem, and vaccine development, to obtain better
tools, and more cost-effective strategy for vector
control and case management, are research areas
offering the greatest prospective(4).
Leishmaniasis comprises a miscellaneous group
of diseases caused by protozoan parasites of the
Leishmania genus. Different clinical manifestations
of leishmaniasis depend both on host genetic control
and infecting species, which are more than 20(5). 
The parasites, which cause heterogeneous
clinical pathway in humans, can be divided in the
subgenus Leishmania (L.) or Viannia (V.).
Cutaneous leishmaniasis (CL) is caused, in the Old
World, by Leishmania (L.) major, Leishmania (L.)
aethiopica, and dermotropic Leishmania (L.) infan-
tum, of the Leishmania subgenus; in the New
World, by Leishmania (L.) mexicana, Leishmania
(L.) amazonensis, Leishmania (L.) venezuelensis,
and dermotropic Leishmania (L.) infantum, of the
Leishmania subgenus ,  and Leishmania (V.)
braziliensis, Leishmania (V.) guyanensis,
Leishmania (V.) lainsoni, Leishmania (V.) naiffi,
Leishmania (V.) panamensis, Leishmania (V.) peru-
viana, and Leishmania shawi, of the Viannia sub-
genus. Mucocutaneous leishmaniasis (MCL), or
espundia, is caused by Leishmaniasis (V.) brazilien-
sis, and Leishmania (V.) panamensis, whereas vis-
ceral leishmaniasis (VL), also named ‘Kala Azar’,
is caused by Leishmania (L.) infantum in the
Mediterranean area, Middle-East and Asian coun-
tries, and Leishmania (L.) chagasi in Latin
America. Leishmania (L.) mexicana and
Leishmania (L.) amazonensis, due to their genotyp-
ic relationships, are now regarded as a single specie
within Leishmania mexicana complex, whereas
Leishmania (L.) infantum and Leishmania (L.) cha-
gasi, together with Leishmania (L.) donovani, are
now considered, due to their genotypic relation-
ships, as a single specie, within the Leishmania
donovani complex. Sometimes, Leishmania infec-
tion may evolve, after recovery, in a chronic CL
form, called ‘Post-Kala Azar Dermal
Leishmaniasis’ (PKDL), which usually need long
and expansive treatments(6,7).
Leishmania are digenetic parasites, developing
as flagellated motile promastigotes in the gut of
blood-sucking female sand flies (Phlebotomus spp.
in the Old Word, Lutzomyia spp. in the New
World), which may be transmitted to the vertebrate
host via dermis during blood-meal, and as obligate
intracellular non-motile amastigotes in phagolyso-
somes of macrophages and dendritic cell of verte-
brate hosts. 
Leishmaniasis is mainly zoonotic disease:
rodents, edentates and marsupials in CL, wild
canines and domestic dogs in zoonotic VL being
the most widespread reservoirs, but others mam-
mals might be too, with the exception of anthro-
ponotic VL (widespread in India), in which man is
the only source of infection(8,9). 
Leishmania can infect mice quite easily, grant-
ing useful in vivo models to evaluate host immune
response and regulation, and genetic control of
infection(10,11).
Immune responses in animal and human
Leishmaniasis 
General aspects
Pathogenesis of leishmaniasis relays to both
parasite factors and host mechanisms, which are
closely linked and interdependent. Inoculation of
promastigotes, via sandfly saliva, is first point of
Leishmania infection, which continues entering
macrophages to escape host responses. Progressive
intracellular infection by amastigotes depends on
the maintenance of macrophages in an inert, inacti-
vated state. Nevertheless, the immunocompetent
hosts develop both non-specific (innate) and anti-
gen-specific (adaptive) cell-mediated responses,
able to control disease evolution, producing (self-
healing disease or asymptomatic infection) or not
(non-healing disease) the desired clinical end-
result(8,12). 
At site of infection, innate responses include
Pattern Recognition Receptors (PPRs, i.e. toll-like
receptors), soluble products (complement, and
released cytokines, including interleukin [IL]-1a,
IL-12, Tumor Necrosis Factor [TNF]) and cells
(neutrophils, monocytes, macrophages, natural
killer [NK] cells, and dendritic cells), which may,
especially IL-12 production, drive induction of
acquired cell-mediated immunity. This complex set
of mechanisms leads to the activation of specific
CD4+ and CD8+ T cells, which, via adhesion mole-
cules and chemokine mechanisms, are actively
recruited to cutaneous or visceral sites, and, sharing
with influxing blood monocytes, direct local
inflammatory responses, including granuloma stag-
ing and lesion development(13-15). 
Massive infiltration of macrophages and
chemokines, such as Monocyte Chemoattractant
Protein-1 (MCP-1), monokine induced by interfer-
on (IFN)-g (MIG), IFN-g-inducible protein-10 (IP-
10), and only low amount of macrophage inflam-
matory protein 1a (MIP-1a) invade sites of
Leishmania infection in dermis of patients affected
by CL(16,17). MCP-1 expression, in skin lesions of
patients with self-healing CL, help healing process
proportionally to increase of its concentration,
whereas high local levels of MIP-1a are associated
with non-healing form of CL. Moreover MCP-1
and IFN-g cooperate to enhance monocytes clear-
ing of intracellular parasites, whereas IL-4 inhibits
effect of MCP-1(16,17).
IFN-g-induced macrophage activation induces
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T helper (TH) 1-type cell responses by development
of a pleiotropic cytokines network, in which IL-12,
produced by activated antigen presenting cells
(APC), i.e. macrophages and dendritic cells, gener-
ates basic response, whereas IFN-g and other
cytokines enhance it(18).
Nevertheless, immune system response is still
partially misunderstood: as a matter of fact, patients
with clinically apparent infections, especially acute
VL (see below), develop not characteristically
polarised TH1- and TH2-type responses, and both
activating (i.e. IL-12, IFN-g,) and suppressive (i.e.
IL-4, IL-10, IL-13, Transforming Growth Factor
[TGF]-b) cytokines patterns may be detected
(19,20). Development of normal counterbalance
mechanisms to curtail inflammation, like in any
other inflammatory environment, may be pointed
out also in acute leishmaniasis(19,20). Change in TH1-
type responses and inactivation of macrophages
may be due to IL-4, IL-10, IL-13 and TGF-b secre-
tion, thereby causing reduction of tissue injury, but
enhancement of intracellular infection(19,20).
Resolution of infection: the TH1 response
Nowadays, the role of a strong type-1
response, as protective immune response against
CL, has been clearly established (15).
Evidences demonstrated that IL-12, from acti-
vated APC, maybe enhanced by other cytokines,
such as IL-1a, IL-18, IL-23 and IL-27, drives dif-
ferentiation and proliferation of TH1 cells, as innate
mechanism response, and induces IFN-g secretion
by TH1 cells and NK cells, as antigen-specific
acquired cell-mediated response(21-23).
Proper activation of immune TH1 cell response
needs both Major Histocompatibility Complex
(MCH) class II antigen presentation and ligation of
co-stimulatory molecules (i.e. B7-1/B7-2 and CD40
on the APC with CD28 and CD40L on the TH1 cell,
respectively)(24,25).
Signals able to regulate superoxide (O2-) and
nitric oxide (NO) production and parasite killing
are induced by IFN-g from TH1 cells, and probably,
to a lesser extent, from CD8+ T cells, as part of the
antigen-specific acquired cell-mediated immune
response, but also by IL-12-activated NK cells, as
part of the innate response. Although molecular
mechanism of NO action on Leishmania is
unknown so far, early data suggested that it could
be directly cytotoxic to the parasites(26,27). The NO-
pathway, thus, appears to be a common mechanism
of Leishmania killing.
Moreover, other cytokines, such as TNF-a,
Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF), Migration Inhibitor Factor
(MIF) and type-1 interferons (IFN-a subtypes and
IFN-b subtype), demonstrated potential ability to
enhance macrophage leishmanicidal activity,
induced by IFN-g and CD40/CD40L interac-
tions(28,29). 
Another important pathway that seems to be
important to develop adequate TH1-mediated resis-
tance to Leishmania infection is Fas/FasL interac-
tion. Activated TH1 lymphocytes induce apoptotic
death in target cells expressing the Fas protein (38).
Furthermore, IFN-g promotes Fas up expression on
membrane surface of macrophages infected with
Leishmania, making them susceptible to CD4+ T
cell-induced apoptotic death(30-31).
Thus, Fas-induced apoptotic death of infected
macrophages might limits the number of host cells
at the site of infection which are required for
amastigote replication(30-31). 
Antigen-specific CD4+ CD25+ T-regulatory
cells, producing IL-10 and TGF-b, moderate activi-
ty of T effectors when infection break off(32,33); so, in
absence of persistent infection, protective immunity
is significantly reduced(32-33).
Non-healing cutaneous Leishmania major
infection: TH2-dependent or defective TH1 response
The TH1-TH2 paradigm of resistance/suscepti-
bility to intracellular infection is largely based on
investigations using Leishmania major. Initial stud-
ies suggested primary role of distinct CD4+ T cell
subsets, TH1 and TH2, producing the counter regu-
latory cytokines, IFN-g and IL-4 respectively, on
the resolution or progression of disease (34,35
However, contradictory reports have been pub-
lished indicating a disease progression role for IL-4
(36). These studies lead to two possible condition:
first, if other regulatory cytokines may be responsi-
ble for immunosuppressive activity previously
attributed to IL-4, and/or if well known defective
TH1 response plays a major role in progressive dis-
ease.
Recent studies, using gene-deficient and trans-
genic mice, have clearly identified other cytokines,
in addition to IL-4, having major roles in non-heal-
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ing response to Leishmania major(36,37). Particularly,
IL-13 has been found to act independently from IL-
4, and the effects of IL-13 and IL-4 might be addi-
tive(37).
Other studies suggest Leishmania major dis-
ease progression may be promoted by IL-10, such
as IL-13 and IL-4. Suppression of IL-12 production
by APC and of IFN-g by CD4+ T and NK cells,
macrophage inactivation and inhibition of their
leishmanicidal functions, identify IL-10 key role in
the pathogenesis of leishmaniasis, especially in the
down-regulation of TH1 responses. Furthermore, T
regulatory cells are significant producers of TGF-b,
which is also partly able to suppress protective
responses(36-38).
Impossibility to produce or respond to IL-12,
and intrinsic defects in APC function or in TH1 cell
development have been hypothesized to explain
inability to mount effective TH1 response, irrespec-
tive of TH2 response. Defective APC function, due
to a failure to produce IL-12, may also underlie in a
deficient APC IL-1 production(39). As a matter of
fact, IL-1 upregulates IL-12 production, as well as
MHC class II co-stimulatory molecule expression,
and mediates the ability of IFN-g to inhibit TH2
response(39). 
Contrariwise, intrinsic defective TH1 cell
development, originally attributed to unfair
response to IL-12, has been associated with down-
regulation of TH1 cell IL-12Rb2 expression (40). It
is well established that IL-12Rβ2 expression can be
downregulated by IL-4 produced by TH2, even
though IL-4-indipendent mechanisms have also
been described(40). Commitment of immune system
to TH2 response has been recently explained by
defective co-polarization of the T cell receptor
(TCR) and the IFN-g receptor complex in naïve
CD4+ T cells during the APC/T precursor interac-
tion(39,40). 
Non-healing cutaneous Leishmania mexicana-
/Leishmania amazonensis infection: IL-4-depen-
dent
IL-4, unlike IL-13, IL-10 and TGF-b, which
are only partially involved, seems to make the
greatest contribution in non-healing cutaneous
Leishmania mexicana infection(41). The Cathepsin L-
like cysteine peptidase (CPB) has been identified as
the likely Leishmania mexicana virulence factor
inducing IL-4 production(42). 
The role of IL-4 in subverting development of
TH1 response has been clearly identified in
Leishmania mexicana infection by several studies;
contrariwise similar studies, on the closely related
parasite Leishmania amazonensis, have no evi-
dence, bordering on secondary role IL-4 in non-
healing Leishmania amazonensis infection(43,44). In
this setting, ability of CPB to proteolytically
degrade the NF-kB family of signalling proteins
might be directly responsible of TH1 responses
inhibition (43,44). Thus, IL-4-independent mecha-
nisms might prevail(43,44). 
Paradox of TH1 and TH2 in visceral leishmaniasis
The dichotomy of TH1 and TH2 cell response,
induced by Leishmania parasites, is even less clear
in VL. Disease progression, in experimental VL by
Leishmania donovani, is due to failure of appropri-
ate TH1 response, rather than to TH2 cell prolifera-
tion(45). As a matter of fact, there is no evidence of
IL-4 exacerbating role in murine VL, and, under
certain circumstances, it can prime for IL-12 pro-
duction and type-1 response(41). 
In the sera, at beginning of infection, patients
infected by Leishmania donovani show high con-
centrations of IFN-g and IL-10, which fall down
within the normal range after undertaking success-
ful chemotherapy(46,47). When performed at time of
diagnosis, peripheral blood mononuclear cells
(PBMC) in vitro stimulation with Leishmania anti-
gens produces low levels of IFN-g and IL-10, but
normal level when same cells are assayed after
recovery(46,47). High concentration of IL-4 may be
detected in supernatants in all the phases of the dis-
ease, whereas IL-4 and IL-2 are undetectable in
sera(46). IL-2 is significantly reduced in supernatants
of actively infected patients, returning to normal
level after recovery(46,47). IL-4 low sera levels might
be related to IFN-g high production, whereas IL-2
sera levels reduction might be due to high sera con-
centration of soluble IL-2 receptor (sIL-2R), which
binds IL-2 with an high affinity mechanism(48).
In spite of the similar secretion pattern of IFN-
g and IL-10 above reported, the control of infection
or complete recovery seems to be associated with
an increased production of IL-2 and IFN-γ(49-51).
Furthermore, IL-10 production correlates with the
progression of VL(52), and its neutralisation, with
specific monoclonal antibody, restores T cell prolif-
eration and IFN-g production in PBMC from acute
VL patients(53). In vitro studies have also demon-
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strated that IL-12 shifts the responses toward TH1-
type and enhances IFN-g production(54).
Therefore, these findings suggest that, in
patients with active VL, the cytokine profile is not
clearly polarized, and both TH1-like and TH2-like
cells appear to proliferate and be activated(46,50,55).
The balance of cytokines at the site of primary acti-
vation of Leishmania-specific cells appears to be of
major importance for the development of TH1 and
TH2 responses(56,57), although other unknown factors
might influence the cellular immune behaviour.
Altogether, data indicate that in symptomatic
patients TH1 cytokine production is not depressed,
but there is an unresponsiveness to the stimuli of
these cytokines, also caused by the high production
of IL-10. Recent studies attention another lym-
phokine, IL-15, for its role against infectious dis-
eases(58) and its ability to enhance both TH1 respons-
es, by increasing IFN-γ production from NK and T
cells(59), and TH2 responses, by augmenting IL-5 and
IL-13 production(60). In particular, it has been
demonstrated that endogenous IL-15 plays a role in
the suppression of TH2 cytokines in acute VL
patients, even though it does not enhance the pro-
duction of TH1 cytokines(61), indicating a potential
protective role of IL-15 against leishmaniasis
caused by the indirect effect on TH1, due to the
restriction of TH2 proliferation(61). Furthermore, IL-
15 in vitro activation of macrophage cultures deter-
mines a significant anti-Leishmania activity, com-
parable to IFN-γ-induced one(62). Leishmania
macrophages intracellular killing, primed by IL-15,
is followed by IL-12 synthesis increase(62).
Altogether, these data indicate IL-15 could, directly
or indirectly, have role as activator of leishmanici-
dal activity, by inducing IL-12 production. 
Non-healing visceral leishmaniasis: TH2-indepen-
dent?
As already mentioned, disease progression and
exacerbating role of TH2 response and IL-4 produc-
tion during Leishmania donovani infection have no
absolute evidence yet. Early studies suggest no cure
rate control due to differential production of TH1
and TH2 cytokines(45), even thought production of
IFN-g correlates with resistance and TH2 cytokines
are not so clearly responsible of susceptibility(63). 
According to this point of view, studies in
mice suggested IL-4 may be protective in some cir-
cumstances, and can promote resistance, rather than
susceptibility, to intracellular pathogens: in effect,
IL-4 and IL-4Ra deficient animals are more suscep-
tible to disease than their wild-type counterparts(64).
IL-4 and IL-4Ra signalling is essential not only for
optimal clearance of Leishmania donovani from
liver and limiting infection in spleen, following pri-
mary infection, but also for effective T cell-depen-
dent chemotherapy, and for vaccine-induced resis-
tance(65). As evidence, in absence of IL-4, type-1
responses and IFN-g production fail to be main-
tained following chemotherapy or to be induced by
vaccination(64,65). 
Though TGF-b has significant disease promot-
ing and progression activity, several studies indicate
IL-10 as major immunosoppressive cytokine in
VL(66). Activation of TH1 cell responses and priming
of parasite killing is allowed by experimental IL-10
inhibition(66,67).
Furthermore, while healing process in suscep-
tible mice is IL-12-dependent, IL-10, but not IL-4
or TGF-b, appears to blunt TH1-type responses and
determine disease fatal outcome(21). 
T cell subset modifications in visceral leishmaniasis
Although data indicate Leishmania donovani
parasites cause immunodepression, exact mecha-
nism they can induce suppression is not clear. As a
matter of fact, levels of CD3+, CD4+ and CD8+ T
cells, in patients affected with symptomatic
Leishmania infantum infection, are within normal
range(46,50).  Whereas, acute VL patients have
markedly reduced levels of memory T cells
(CD3+/CD45RO+) compared with healthy controls,
which come back to normal levels as result of suc-
cessful chemotherapy(46,50,68,69). Contrariwise, all
patients affected with asymptomatic infection and
positive leishmanin (or Montenegro) skin test,
intradermically performed using culture of pro-
mastigotes as antigen, show marked increment of
memory CD4+ T(68). Importance of increased memo-
ry CD4+ T cells level in this group of patients and
the relationship with positive leishmanin skin test
and acquired immunity needs further explana-
tion(68,69). Elevated number of CD3+ HLA-DR+ lym-
phocytes and increased expression of HLA-DR
antigen on these cells show strong activation of
cell-mediated immune response in acute VL
patients(46). 
The role of apoptosis and CD8+ T cells in
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Leishmania infection
As aforesaid, defective host-cellular responses
to challenge with pathogenic infectious agents may
be caused by induction of T cell apoptosis, either in
mice or in humans(70-73). In experimental VL it has
been demonstrated that infection of susceptible host
results in CD4+ T cell apoptosis and reductions of
TH1 cytokine production(73).
In particular, it has been demonstrated that
apoptotic mechanisms, mainly operating through
the Fas (APO-1/CD95) pathway, grant resistance to
Leishmania major, and singeneic gld and lpr mice,
lacking of functional Fas system, fail healing their
lesions(74). However, mice infected by Leishmania
donovani parasites show increased incidence of T
cell apoptosis in liver and spleen(75). Leukocyte
apoptosis seems to be involved in VL patients too,
both in acute and in healed phases of disease.
In fact, monocytes and T lymphocytes from
acute VL patients show significantly higher apopto-
sis levels compared to observed in healed subjects
ones. T lymphocytes rate of apoptotic cells was far
greater than monocytes one(31). T cells were mainly
of CD4+ phenotype(31,76). In particular, TH1 subset,
evaluated by chemokine receptor-5 (CCR5), is
involved in this process and used CD95-mediated
mechanism (31). These data, pointing out signifi-
cant increase in apoptosis of TH1-like subset (15-
20% of CD4+ cells), correlate with studies, carried
out in susceptible hosts, showing enhancement of
CD4+ T cell apoptosis, especially TH1-like cells
subtype, associated to reduction of TH1 cytokine
production(73). Deletion of CD4+ TH1-like cells
could contribute to depress cell-mediated immunity
in acute VL patients, since TH1 cytokines appears
to be involved in protection against leishmaniasis,
both in experimental models(27,73) and in human
infections(57-59).
Contrariwise, higher apoptosis frequency in
CD8+ T cells rather than in CD4+ T ones has been
pointed out in active human localised CL, and these
apoptotic events were very low in patients with
self-healing lesions(76). Thus, cell-mediated immuni-
ty failure, responsible of severe immunodepression
in various forms of leishmaniasis, can be attributed
to inappropriate and missregulated T-cell death.
The amount of available data suggests CD8+ T
cells are involved in leishmanicidal activity, and
this last one seems to be modulated by IFN-g and
IL-2 secretion(77). Variety of effector mechanisms by
these CD8+ T cells, involving direct cytotoxic
activity, via perforin/granzyme pathway, and apop-
tosis induction, via Fas/FasL interaction, have been
highlighted in several reports(76-78).
Moreover, CD8+ lymphocytes secrete various
cytokines (especially IFN-γ) and chemokines (espe-
cially ones belonging to C-C group, i.e. Regulated
upon Activation, Normal T-cell Expressed, and pre-
sumably Secreted [RANTES]), which might have
key role in acquired cell-mediated immunity
against parasite, i.e. by promoting CD4+ TH1 cell
development(78). 
Perforin/granzyme-mediated direct cytotoxici-
ty and parasitized macrophages apoptosis induction
are candidate mechanisms employed by CD8+ T
cells in their effort to limit parasite multiplication(76). 
Post Kala Azar dermal leishmaniasis
In most cases of PKDL, parasites or parasites
antigens were observed in all the lesions and were
able to induce the formation of an inflammatory
infiltrate, consisting of a mixture of macrophages,
lymphocytes and plasma cells(79). The inflammatory
cells were mainly CD3+ and IL-10 was the most
prominent cytokine founded in lesions(80). However,
IFN-g was found in all and IL-4 in most lesions in
varying amounts(79-80).
Conclusions
Cytokines response pattern and clinical
Leishmania outcome are strictly connected. Type-1
lymphocyte immune response and IFN-g produc-
tion have been clearly identified as protective
immune factors against Leishmania, whereas defi-
nite role of TH2 cytokines, in non-healing infec-
tions, requires careful exploration. As a matter of
fact, appropriate CL models show IL-4 and IL-13
(TH2 cytokines) can promote disease progression,
whereas IL-4 role in VL is not well defined, as its
ability to enhance protective type-1 response.
Thus, immune response to intracellular para-
sites should dismiss TH1/TH2 paradigm of resis-
tance/susceptibility, embracing theory of a more
complicated network of regulatory/counter regula-
tory interactions, and IL-4 role in influencing
Leishmania infection is waiting for future re-evalu-
ation, according to Leishmania species involved,
host organism used and tissue site examined.
Moreover, the presence of antigen specific regulato-
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ry T cell subsets may provide an environment that
contributes to the balance between TH1 and TH2
cells.
References
1) Dantas-Torres F, Brandao-Filho SP. Visceral leishmani-
asis in Brazil: revisiting paradigms of epidemiology
and control. Rev Inst Med Trop Sao Paulo 2006; 48:
151-6. 
2) Bern C, Chowdhury R. The epidemiology of visceral
leishmaniasis in Bangladesh: prospects for improved
control. Indian J Med Res 2006; 123: 275-88.
3) Steffen R, Rickenbach M, Wilhelm U, Helminger A,
Schar M. Health problems after travel to developing
countries. J Infect Dis 1987; 156: 84-91.
4) Murray HW, Berman JD, Davies CR and Saravia NG.
Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
5) Croft SL, Vivas L and Brooker S. Recent advances in
research and control of malaria, leishmaniasis, try-
panosomiasis and schistosomiasis. East Mediterr
Health J 2003; 9: 518-33.
6) Thomaz-Soccol V, Lanotte G, Rioux J A, Pratlong F,
Martini-Dumas A and Serres E. Phylogenetic taxonomy
of New World Leishmania. Ann Parasitol Hum Comp
1993; 68: 104-6.
7) Gramiccia M And Gradoni L. The current status of
zoonotic leishmaniases and approaches to disease con-
trol. Int J Parasitol 2005; 35: 1169-80.
8) Bates PA and Rogers ME. New insights into the devel-
opmental biology and transmission mechanisms of
Leishmania. Curr Mol Med 2004; 4: 601-9.
9) Colmenares M, Kar S, Goldsmith-Pestana K and
McMahon-Pratt D. Mechanisms of pathogenesis: dif-
ferences amongst Leishmania species. Trans R Soc
Trop Med Hyg 2002; 96: S3-7.
10) Gumy A, Louis JA and Launois P. The murine model of
infection with Leishmania major and its importance for
the deciphering of mechanisms underlying differences
in Th cell differentiation in mice from different genetic
backgrounds. Int J Parasitol 2004; 34: 433.
11) Louis JA, Gumy A, Voigt H, Launois P and Rocken M.
The use of the murine model of infection with
Leishmania major to reveal the antagonistic effects that
IL-4 can exert on T helper cell development and
demonstrate that these opposite effects depend upon the
nature of the cells targeted for IL-4 signaling. Pathol
Biol 2003; 51: 71.
Advances in leishmaniasis immunopathogenesis 13
Disease
Healing Non healing
CD4+ T-cell Cytokines CD4+ T-cell Cytokines
Cutaneous
leishmaniasis
TH1 Leishmania major, mexicana, amazonensis:
IL-12, IL-1α, IL-18,
IL-23, IL-27, IFN-γ,
TNF-α, MIF, IFN-α,
IFN-β, GM-CSF, IL-10, TGF-β
Leishmania major:
excessive TH2 response
and/or defective APC function
and/or defective TH1 response
Leishmania mexicana:
excessive TH2 response
and/or defective APC function
and/or defective TH1 response
Leishmania amazonensis:
excessive TH2 response
and/or defective APC function
and/or defective TH1 response
IL-4 (?), IL-13,
IL-10, TGF-β
IL-4, IL-13 (?), 
IL-10 (?)
IL-4 (?)
Visceral
leishmaniasis
TH1
TH2 (?)
TH1
TH2 (?)
IL-12, IL-4 (?)
(experimental visceral leishmaniasis)
IL-2, IFN-γ, IL-12, IL-15, IL-4 (?)
(human visceral leishmaniasis)
Experimental visceral leishmani-
asis:
defective TH1 response (?)
excessive TH2 response (?)
Human visceral leishmaniasis:
defective TH1 response (?) 
excessive TH2 response (?)
IL-4 (?), IL-10, 
TGF-β (?)
IL-4 (?), IL-10,
TGF-β (?)
CD: cluster of differentation
TH1: T helper 1
TH2: T helper 2 
APC: antigen presenting cells
IL: interleukin
IFN-α: interferon-α
IFN-β: interferon-β
IFN-γ: interferon-γ
MIF: Migration Inhibitor Factor 
TGF-β: Transforming Growth Factor-β
TNF-α: Tumor Necrosis Factor-α
GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor
Table 1: Types of CD4+ T-cells and cytokines involved in different forms of leishmaniasis
12) Vannier-Santos MA, Martiny A and de Souza W. Cell
biology of Leishmania spp.: invading and evading.
Curr Pharm Des 2002; 8: 297. 
13) McSorley S, Proudfoot L, O’Donnell CA and Liew FY.
Immunology of murine leishmaniasis. Clin Dermatol
1996; 14: 451.
14) Barbieri CL. Immunology of canine leishmaniasis.
Parasite Immunol. 2006; 28: 329.
15) Roberts MT. Current understandings on the immunolo-
gy of leishmaniasis and recent developments in preven-
tion and treatment. Br Med Bull 2006 ; 75-76: 115-30.
16) Steigerwald M and Moll H. Leishmania major modu-
lates chemokine and chemokine receptor expression by
dendritic cells and affects their migratory capacity.
Infect Immun 2005; 73: 2564-7.
17) Ritter U and Moll H. Monocyte chemotactic protein-1
stimulates the killing of Leishmania major by human
monocytes, acts synergistically with IFN-gamma and is
antagonized by IL-4. Eur J Immunol 2000; 30: 3111-20.
18) Constantinescu CS, Hondowicz BD, Elloso MM,
Wysocka M, Trinchieri G and Scott P. The role of IL-12
in the maintenance of an established Th1 immune
response in experimental leishmaniasis. Eur J Immunol
1998; 28: 2227-33. 
19) Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK,
Hansen MB, Koech DK, Kharazmi A and Theander TG.
Leishmania donovani-reactive Th1- and Th2-like T-cell
clones from individuals who have recovered from viscer-
al leishmaniasis. Infect Immun 1993; 61: 1069-73. 
20) Chtanova T and Mackay CR. T cell effector subsets:
extending the Th1/Th2 paradigm. Adv Immunol 2001;
78: 233-66.
21) Bacellar O, D’oliveira A Jr, Jeronimo S and Carvalho
EM. IL-10 and IL-12 are the main regulatory cytokines
in visceral leishmaniasis. Cytokine 2000; 12: 1228-31. 
22) Murray HW, Tsai CW, Liu J and Ma X. Responses to
Leishmania donovani in mice deficient in interleukin-
12 (IL-12), IL-12/IL-23, or IL-18. Infect Immun 2006;
74: 4370-4. 
23) Artis D, Johnson LM, Joyce K, Saris C, Villarino A,
Hunter CA and Scott P. Cutting edge: early IL-4 pro-
duction governs the requirement for IL-27-WSX-1 sig-
naling in the development of protective Th1 cytokine
responses following Leishmania major infection. J
Immunol 2004; 172: 4672-5. 
24) Elloso MM and Scott P. Expression and contribution of
B7-1 (CD80) and B7-2 (CD86) in the early immune
response to Leishmania major infection. J Immunol
1999; 162: 6708-15. 
25) Padigel UM and Farrell JP. CD40-CD40 ligand costim-
ulation is not required for initiation and maintenance
of a Th1-type response to Leishmania major infection.
Infect Immun 2003; 71: 1389-95. 
26) Holzmuller P, Bras-Goncalves R and Lemesre JL.
Phenotypical characteristics, biochemical pathways,
molecular targets and putative role of nitric oxide-
mediated programmed cell death in Leishmania.
Parasitology 2006; 132: S19-32. 
27) Liew FY, Wei XQ and Proudfoot L. Cytokines and
nitric oxide as effector molecules against parasitic
infections. Phil Trans R Soc Lond B 1997; 352: 1311-5. 
28) Al-Zamel F, Al-Shammary FJ, El-Shewemi S and
Soliman R. Enhancement of leishmanicidal activity of
human macrophages against Leishmania major and
Leishmania donovani infection using recombinant
human granulocyte macrophage colony stimulating
factor. Zentralbl Bakteriol 1996; 285: 92-105. 
29) Nunes MP, Cysne-Finkelstein L, Monteiro BC, de
Souza DM, Gomes NA and DosReis GA. CD40 signal-
ing induces reciprocal outcomes in Leishmania-infect-
ed macrophages; roles of host genotype and cytokine
milieu. Microbes Infect 2005; 7: 78-85.
30) Eidsmo L, Nylen S, Khamesipour A, Hedblad MA,
Chiodi F and Akuffo H. The contribution of the
Fas/FasL apoptotic pathway in ulcer formation during
Leishmania major-induced cutaneous Leishmaniasis.
Am J Pathol 2005; 166: 1099-108. 
31) Potestio M, D’Agostino P, Romano GC, Milano S,
Ferlazzo V, Aquino A, Di Bella G, Caruso R, Gambino
G, Vitale G, Mansueto S and Cillari E. CD4+ CCR5+
and CD4+ CCR3+ lymphocyte subset and monocyte
apoptosis in patients with acute visceral leishmaniasis.
Immunology 2004; 113: 260-8. 
32) Belkaid Y. The role of CD4(+)CD25(+) regulatory T
cells in Leishmania infection. Expert Opin Biol Ther
2003; 3: 875-85.
33) Kariminia A, Bourreau E, Pascalis H, Couppie P,
Sainte-Marie D, Tacchini-Cottier F and Launois P.
Transforming growth factor beta 1 production by
CD4+ CD25+ regulatory T cells in peripheral blood
mononuclear cells from healthy subjects stimulated
with Leishmania guyanensis. Infect Immun 2005; 73:
5908-14. 
34) Aguilar-Torrentera F and Carlier Y. Immunological fac-
tors governing resistance and susceptibility of mice to
Leishmania major infection. Rev Latinoam Microbiol
2001; 43: 135-42.
35) Sacks D and Noben-Trauth N. The immunology of sus-
ceptibility and resistance to Leishmania major in mice.
Nat Rev Immunol 2002; 2: 845-58.
36) Noben-Trauth N, Lira R, Nagase H, Paul WE and
Sacks DL. The relative contribution of IL-4 receptor
signaling and IL-10 to susceptibility to Leishmania
major. J Immunol 2003; 170: 5152-8. 
37) Matthews DJ, Emson CL, McKenzie GJ, Jolin HE,
Blackwell JM and McKenzie AN. IL-13 is a suscepti-
bility factor for Leishmania major infection. J Immunol
2000; 164: 1458-62. 
38) Li J, Hunter CA and Farrell JP. Anti-TGF-beta treat-
ment promotes rapid healing of Leishmania major
infection in mice by enhancing in vivo nitric oxide pro-
duction. J Immunol 1999; 162: 974-9.
39) Shankar A H and Titus R G. The influence of antigen-
presenting cell type and interferon-gamma on priming
and cytokine secretion of Leishmania major-specific T
cells. J Infect Dis 1997; 175: 151-7. 
40) Chakir H, Campos-Neto A, Mojibian M and Webb JR.
IL-12Rbeta2-deficient mice of a genetically resistant
background are susceptible to Leishmania major infec-
tion and develop a parasite-specific Th2 immune
response. Microbes Infect 2003; 5: 241-9. 
41) Alexander J and Bryson K. T helper (h)1/Th2 and
Leishmania: paradox rather than paradigm. Immunol
Lett 2005; 99: 17-23.
42) Denise H, McNeil K, Brooks DR, Alexander J,
Coombs GH and Mottram JC. Expression of multiple
CPB genes encoding cysteine proteases is required for
Leishmania mexicana virulence in vivo. Infect Immun
14 P. Mansueto - G. Vitale et Al
2003; 71: 3190-5. 
43) Ueda-Nakamura T, da Conceicao Rocha Sampaio M,
Cunha-e-Silva NL, Traub-Cseko YM and de Souza W.
Expression and processing of megasome cysteine pro-
teinases during Leishmania amazonensis differentia-
tion. Parasitol Res 2002; 88: 332-7. 
44) Cameron P, McGachy A, Anderson M, Paul A, Coombs
GH, Mottram JC, Alexander J and Plevin R. Inhibition
of lipopolysaccharide-induced macrophage IL-12 pro-
duction by Leishmania mexicana amastigotes: the role
of cysteine peptidases and the NF-kappaB signaling
pathway. J Immunol 2004; 173: 3297-304. 
45) Kaye PM, Curry AJ and Blackwell JM. Differential
production of Th1- and Th2-derived cytokines does not
determine the genetically controlled or vaccine-
induced rate of cure in murine visceral leishmaniasis. J
Immunol 1991; 146: 2763-70. 
46) Cillari E, Vitale G, Arcoleo F, D’Agostino P, Mocciaro
C, Gambino G, Malta R, Stassi G, Giordano C and
Milano S. In vivo and in vitro cytokine profiles and
mononuclear cell subsets in Sicilian patients with
active visceral leishmaniasis. Cytokine 1995; 7: 740-5. 
47) Ansari NA, Saluja S and Salotra P. Elevated levels of
interferon-gamma, interleukin-10, and interleukin-6
during active disease in Indian kala azar. Clin
Immunol 2006; 119: 339-45.
48) Vitale G, Reina G, Mansueto S, Malta R, Gambino G,
Mocciaro C, D’Agostino R, Dieli M and Cillari E. The
significance of serum soluble IL-2 receptor as a marker
for active visceral leishmaniasis in Sicilian patients.
Clin Exp Immunol 1992; 90: 219-22. 
49) Cillari E, Liew FY, Lo Campo P, Milano S, Mansueto S
and Salerno A. Suppression of IL-2 production by cry-
opreserved peripheral blood mononuclear cells from
patients with active visceral leishmaniasis in Sicily. J
Immunol 1988; 140: 2721-6.
50) Cillari E, Milano S, Dieli M, Maltese E, Di Rosa S,
Mansueto S, Salerno A and Liew FY. Reduction in the
number of UCHL-1+ cells and IL-2 production in the
peripheral blood of patients with visceral leishmania-
sis. J Immunol 1991; 146: 1026-30. 
51) Carvalho EM, Badaro R, Reed SG, Jones TC and
Johnson WD. Absence of gamma interferon and inter-
leukin-2 production during active visceral leishmania-
sis. J Clin Invest 1985; 76: 2066-9.
52) Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M,
Hashim FA, el-Hassan AM, Russo DM and Reed SG.
Interleukin 10 production correlates with pathology in
human Leishmania donovani infections. J Clin Invest
1993; 92: 324-9. 
53) Carvalho EM, Bacelar O, Brownell CE, Regis T,
Coffman RL and Reed SG. Restoration of IFN-gamma
production and lymphocyte proliferation in visceral
leishmaniasis. J Immunol 1994; 152: 5949-56.
54) Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-
Hassan AM, Grabstein KH, Trinchieri G and Reed SG.
IL-12 enhances Th1-type responses in human
Leishmania donovani infections. J Immunol 1995; 154:
4623-9.
55) Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R,
Bern C and Secor WE. Multiplex analysis of circulating
cytokines in the sera of patients with different clinical
forms of visceral leishmaniasis. Cytometry A 2006; 69:
353-8. 
56) Kemp M, Theander TG and Kharazmi A. The contrast-
ing roles of CD4+ T cells in intracellular infections in
humans: leishmaniasis as an example. Immunol Today
1997; 17: 13-6.
57) Romagnani S. The Th1/Th2 paradigm. Immunol Today
1997; 18: 263-6.
58) Woldmann TA and Tagaya Y. The multifaceted regula-
tion of interleukin-15 expression and the role of this
cytokine in NK cell differentiation and host response to
intracellular pathogens. Annu Rev Immunol 1999; 17:
19-49.
59) Lauwerys BR, Garot N, Renauld JC and Houssiau FA.
Cytokine production and killer activity of NK/T-NK
cells derived with IL-2, IL-15, or the combination of IL-
12 and IL-18. J Immunol 2000; 165: 1847-53.
60) Loza MJ, Zamai L, Azzoni L, Rosati E and Perussia B.
Expression of type 1 (interferon gamma) and type 2
(interleukin-13, interleukin-5) cytokines at distinct
stages of natural killer cell differentiation from progen-
itor cells. Blood 2002; 99: 1273-81.
61) Milano S, Di Bella G, D’Agostino P, Barbera C, Caruso
R, La Rosa M, Ferlazzo V, Vitale G, La Russa C,
Gambino G, Chifari N, Mansueto S and Cillari E. IL-15
in human visceral leishmaniasis caused by Leishmania
infantum. Clin Exp Immunol 2002; 127: 360-5. 
62) D’Agostino P, Milano S, Arcoleo F, Di Bella G, La
Rosa M, Ferlazzo V, Caruso R, Chifari N, Vitale G,
Mansueto S and Cillari E. Interleukin-15, as interferon-
gamma, induces the killing of Leishmania infantum in
phorbol-myristate-acetate-activated macrophages
increasing interleukin-12. Scand. J Immunol 2004; 60:
609-14. 
63) Lehmann J, Enssle KH, Lehmann I, Emmendorfer A
and Lohmann-Matthes ML. The capacity to produce
IFN-gamma rather than the presence of interleukin-4
determines the resistance and the degree of susceptibil-
ity to Leishmania donovani infection in mice . J
Interferon Cytokine Res 2000; 20: 63-77. 
64) Satoskar A, Bluethmann H and Alexander J. Disruption
of the murine interleukin-4 gene inhibits disease pro-
gression during Leishmania mexicana infection but
does not increase control of Leishmania donovani
infection. Infect Immun 1995; 63: 4894-9. 
65) Stager S, Alexander J, Carter KC, Brombacher F and
Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor
alpha signaling contribute to the development of hepat-
ic granulomas with optimal antileishmanial activity.
Infect Immun 2003; 71: 4804-7. 
66) Wilson ME, Young BM, Davidson BL, Mente KA and
McGowan SE. The importance of TGF-beta in murine
visceral leishmaniasis. J Immunol 1998; 161: 6148-55. 
67) Murray HW, Flanders KC, Donaldson DD, Sypek JP,
Gotwals PJ, Liu J and Ma X. Antagonizing deactivating
cytokines to enhance host defense and chemotherapy in
experimental visceral leishmaniasis. Infect Immun
2005; 73: 3903-11. 
68) Gollob KJ, Antonelli LR and Dutra WO. Insights into
CD4+ memory T cells following Leishmania infection.
Trends Parasitol 2005; 21: 347-50. 
69) Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F
and Kager PA. T cell subset and cytokine profiles in
human visceral leishmaniasis during active and asymp-
tomatic or sub-clinical infection with Leishmania dono-
vani. Clin Immunol 2005; 117: 182-91.
Advances in leishmaniasis immunopathogenesis 15
70) Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM,
Bourez JM and Ameisen JC. T helper type 1/T helper
type 2 cytokines and T cell death: preventive effect of
interleukin 12 on activation-induced and CD95
(FAS/APO-1)-mediated apoptosis of CD4+ T cells from
human immunodeficiency virus-infected persons. J Exp
Med 1995; 182: 1759-67.
71) Dockrell DH. Apoptotic cell death in the pathogenesis
of infectious diseases. J Infect 2001; 42: 227-34.
72) Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW,
Hallahan CW, Kovacs JA, Davey RT and Lane HC.
CD4 T cell expansions are associated with increased
apoptosis rates of T lymphocytes during IL-2 cycles in
HIV infected patients. AIDS 2001; 15: 1765-75. 
73) Das G, Vohra H, Rao K, Saha B and Mishra GC.
Leishmania donovani infection of a susceptible host
results in CD4+ T-cell apoptosis and decreased Th1
cytokine production. Scand J Immunol 1999; 49: 307-10.
74) Conceicao-Silva F, Hahne M, Schroter M, Louis J and
Tschopp J. The resolution of lesions induced by
Leishmania major in mice requires a functional Fas
(APO-1, CD95) pathway of cytotoxicity. Eur J Immunol
1998; 28: 237-45.
75) Alexander CE, Kaye PM and Engwerda CR. CD95 is
required for the early control of parasite burden in the
liver of Leishmania donovani-infected mice. Eur J
Immunol 2001; 31: 1199-210.
76) Bertho AL, Santiago MA, Da-Cruz AM and Coutinho
SG. Detection of early apoptosis and cell death in T
CD4+ and CD8+ cells from lesions of patients with
localized cutaneous leishmaniasis. Braz J Med Biol
Res 2000; 33: 317-25. 
77) Tsagozis P, Karagouni E and Dotsika E. Function of
CD8+ T lymphocytes in a self-curing mouse model of
visceral leishmaniasis. Parasitol Int 2005; 54: 139-46. 
78) Tsagozis P, Karagouni E and Dotsika E. CD8(+) T cells
with parasite-specific cytotoxic activity and a Tc1 pro-
file of cytokine and chemokine secretion develop in
experimental visceral leishmaniasis. Parasite Immunol
2003; 25: 569-79. 
79) Sharma MC, Gupta AK, Verma N, Das VN, Saran R
and Kar SK. Demonstration of Leishmania parasites in
skin lesions of Indian post kala-azar dermal leishmani-
asis (PKDL) cases. J Commun 2000; Dis. 32: 67-8.
80) Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru
AE, Moller T, Kharazmi A and Theander TG.
Immunopathology of post kala-azar dermal leishmania-
sis (PKDL): T-cell phenotypes and cytokine profile. J
Pathol 1999; 189: 615-22. 
_________
Request reprints from:
Prof. PASQUALE MANSUETO
Dipartimento di Medicina Clinica e delle Patologie Emergenti
Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’
Via del Vespro, 141
90127 Palermo
(Italy)
16 P. Mansueto - G. Vitale et Al
